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LETTER TO THE EDITOR
Antimicrobial susceptibilities and ESBL production rates of
Salmonella and Shigella strains inTurkey
Acute bacterial diarrhea is an important cause of morbidity and
public health concern in Turkey, especially in children [1]. To
determine the antibiotic susceptibility patterns and extended-
spectrum b-lactamase (ESBL) activity, we evaluated consecutive
strains of Salmonella and Shigella spp. isolated from community-
acquired infections from three different centers in Ankara,
Turkey.
In vitro antibiotic susceptibilities of Shigella (117) and Salmo-
nella (84) strains were determined by disc diffusion method,
according to the instructions of the NCCLS [2]. Production of
ESBL was determined by double disc synergy and inhibitor-
potentiated disc diffusion tests. The distribution of strains were
81 (41%) Sh. sonnei, 32 (16%) Sh. ﬂexneri, three (1%) Sh.
dysenteriae, one (1%) Sh. boydii, 45 (22%) Salmonella group B
(26 Sal. typhimurium), 31 (15%) Salmonella group D (21 Sal.
typhi), seven (3%) group C and one (1%) Salmonella group A
(Tables 1 and 2).
A multi-resistance pattern was seen most frequently in Sh.
ﬂexneri and Sal. typhimurium strains. All Shigella and Salmonella
strains were susceptible to ciproﬂoxacin and imipenem. We
detected ESBL activity in four Sal. typhimurium strains and, to
the best of our knowledge, this is the ﬁrst report of ESBL-
producing Salmonella strains from community-acquired infec-
tions in our country.
First-line antibiotics such as ampicillin, trimethoprim-sulfa-
methoxazole (TMP-SMX) and chloramphenicol have alarming
resistance rates, and occur world-wide [2–6]. ESBL production
was ﬁrst identiﬁed in 1984, fron nosocomial Salmonella strains
[7]. This enzyme was thought to spread among other Enter-
obactericeae species, resulting in widespread ESBL production
[8,9]. Also, the PER-1 enzyme has been previously isolated
among hospital-acquired Sal. typhimurium strains in Turkey,
creating further awareness of the clinical and environmental
implications [5].
In this study, 11 of 32 (35.4%) Sh. ﬂexneri, three of 81 (3.7%)
Sh. sonnei and one Sh. dysanteriae isolates had multi-resistant
patterns, but no ESBL activity was determined in any. Five of 84
Salmonella isolates (6%) were also found to be multi-resistant, all
Sal. typhimurium including four with ESBL activity. ESBL-
producing strains showed in vitro resistance to ampicillin,
ceftriaxone, ceftazidim, cefotaxime and aztreonam. No ﬂuor-
oquinolone or imipenem resistance was found in any strains,
including ESBL-producing strains.
Increasing resistance to commonly used antimicrobial agents
in Shigella and Salmonella species has become a major public
health concern world-wide [10]. Among Shigella strains, plas-
mid-borne resistance against ﬁrst-line antibiotics such as ampi-
cillin, choramphenicol and tetracycline have been reported
globally [11]. In Sh. ﬂexneri, high antibiotic resistance rates,
multi-resistant patterns and plasmid-associated b-lactamase pro-
duction are more frequent [3,11,12]. In this study, Sh. sonneiwas
the most frequently isolated species, but higher antibiotic
resistance rates and multi-resistant patterns were found in Sh.
ﬂexneri strains; these ﬁndings are in close accordance with other
studies carried out in our country [1,4,11]. Even higher resis-
tance rates were found in Sal. typhimurium strains. The highest
rate of ampicillin resistance was detected in non-typhi Salmo-
nella group D, although evaluation of these results is rather
difﬁcult due to the very small number of strains used in our
study.
Chloramphenicol has been used as a ﬁrst antimicrobial agent
in Sal. typhi infection for many years, and the ﬁrst epidemic
with chloramphenicol resistance was reported in 1972, in
Mexico [6,13]. This resistance encoded via plasmids and fre-
quently occurred together with streptomycin, sulfonamides and
tetracycline resistance [11]. Since 1989, infections with multi-
resistant strains have been reported in many countries, especially
Pakistan and India [6].
In a Turkish study published in 1994, no Sal. typhi strains
were reported resistant to ampicillin, TMP/SMX and chlor-
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Table 1 The distribution of Shigella strains and their antibiotic susceptibility results
Sh. sonnei (n ¼ 81)
Number susceptible (%)
Sh. flexneri (n ¼ 32)
Number susceptible (%) Sh. dysenteriae (n ¼ 3) Sh. boydi (n ¼1)
Ampicillin 71 (88) 5 (16) 1 1
TMP/SMX 46 (57) 17 (53) 2 1
Chloramphenicol 76 (93) 11 (34) 2 1
Ciprofloxacin 81 (100) 32 (100) 3 1
Ceftriaxone 81 (100) 32 (100) 3 1
Imipenem 81 (100) 32 (100) 3 1
amphenicol. However, in a recent study carried out by the same
investigators, 16% of Sal. typhi strains were found to be multi-
resistant to all three antibiotics [4,14]. In our study, ampicillin,
chloramphenicol and TMP/SMX resistance of Sal. typhi strains
was detected in 13%, 7% and 7% of strains, respectively, and we
consider that there is a growing resistance problem in Salmonella
strains in Turkey. Fluoroquinolone resistance was not found in
any of our Salmonella strains, although quinolone resistance has
been reported in developing countries [6]. Our study raises
concerns about ESBL in community-originated Sal. typhimur-
ium strains, one of the most frequently isolated serotypes among
human salmonellosis.
In conclusion, ampicillin, choramphenicol and TMP/SMX
are no longer empiric treatment alternatives for acute diarrheal
infections acquired in Turkey and it is believed that early
determination and closer epidemiologic observation would
have a signiﬁcant impact on the prevention of expansion of
new resistance forms.
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Table2 The antimicrobial susceptibilities and ESBL production of Salmonella isolates
Sal. typhimurium
(n ¼ 26)
Number (%)
Group Ba
(n ¼19)
Number (%)
Group C
(n ¼ 7)
Number
Group Db
(n ¼10)
Number (%)
Sal. typhi
(n ¼ 21)
Number (%)
Ampicillin 16(62) 16(84) 7 2(20) 19(87)
TMP/SMX 23(88) 19(100) 7 10(100) 20(93)
Chloamphenicol 16(62) 16(84) 6 10(100) 20(93)
Ciprofloxacin 26(100) 19(100) 7 10(100) 21(100)
Ceftriaxone 22(85) 19(100) 7 10(100) 21(100)
Imipenem 26(100) 19(100) 7 10(100) 21(100)
ESBL 4(15) 0(0) 8 0(0) 0(0)
aExcept Sal. typhimurium strains; bExcept Sal. typhi strains.
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